Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood–Brain Barrier

Authors:

Abstract
Pretargeted PET imaging offers a powerful approach to improve nuclear imaging contrast and reduce systemic radiation exposure, yet its application in the brain has been limited by the blood-brain barrier (BBB). Here, we demonstrate, for the first time, successful pretargeted PET imaging of a brain target enabled by a bispecific antibody engineered for transferrin receptor-mediated BBB transcytosis. By combining this brain shuttle with a novel 18F-labeled tetrazine, we achieve specific, quantifiable detection of brain-localized Aβ aggregates, validated through PET imaging and histological analysis. This proof-of-concept establishes a versatile, noninvasive imaging platform with broad potential for assessing biologic drug candidates and CNS targets previously considered intractable.
Funding Information
  • Kr?ftens Bek?mpelse
  • Danmarks Frie Forskningsfond (8022-00187B)
  • Novo Nordisk Fonden (NNF23OC0082288, NNF23SA0087869)
  • HORIZON EUROPE Marie Sklodowska-Curie Actions (101110589)
  • Horizon 2020 Framework Programme (668532, 670261)
  • Innovationsfonden
  • Lundbeck Foundation
  • Research Foundation of Rigshospitalet

This publication has 39 references indexed in Scilit: